[New anti-obesity medications. Prescription and follow-up].

Abstract

The treatment of obesity is complex and relies on interdisciplinary follow-up. The new medications promote weight loss without addressing the underlying causes of overweight or obesity. Medication alone, without an interdisciplinary approach, can be detrimental to the patient due to the significant risk of therapeutic failure. These medications do not meet the reimbursement criteria, and the prescribing physician must submit a request for reimbursement authorization and periodically report to the health insurance. The initiation, follow-up, and discontinuation of pharmacological treatment of obesity must be undertaken in partnership between the person living with obesity and the obesity specialist.